The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing.
Under the terms of the agreement, Biocon Biologics has secured a launch date for the product no later than July 1, 2025, it added.
Yesafili, an ophthalmology product, is intended for the treatment of neovascular (wet AMD), age-related macular degeneration, among other issues.
In March 2023, Health Canada had granted tentative approval for Yesafili (2 mg vials), subject to the resolution of any patent issues, Biocon Biologics said
The settlement resolves multiple parallel patent infringement proceedings in the Federal Court of Canada involving six patents, and associated judicial review proceedings, under Canada’s Patented Medicines (Notice of Compliance) Regulations addressing pre-entry pharmaceutical patent litigation, it noted.
